Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations

Although clinical outcomes for people with CF (PwCF) have dramatically improved over the last several decades, pulmonary exacerbations (PEx) remain common. PEx are clinically important events that are associated with significant morbidity and reduced quality of life. Optimal PEx diagnosis and management strategies for PwCF remain unclear, particularly in an era of highly effective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapy (HEMT). PEx treatment guidelines do exist [1], yet most of the recommendations are consensus- rather than evidenced-based.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Source Type: research